Suppr超能文献

相似文献

1
2
Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Cancer Cell. 2009 Sep 8;16(3):174-6. doi: 10.1016/j.ccr.2009.08.012.
3
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Leuk Res. 2011 Oct;35(10):1355-9. doi: 10.1016/j.leukres.2011.04.020. Epub 2011 May 13.
4
[Research advance on molecular genetics of CML blast crisis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21.
6
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5. doi: 10.1073/pnas.0606509103. Epub 2006 Oct 31.
10
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Eur J Haematol. 2003 Apr;70(4):235-9. doi: 10.1034/j.1600-0609.2003.00046.x.

引用本文的文献

1
Common origins of autoimmune diseases and lymphoid malignancies.
Trends Immunol. 2025 Aug 14. doi: 10.1016/j.it.2025.07.010.
2
Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models.
Cureus. 2025 Apr 8;17(4):e81889. doi: 10.7759/cureus.81889. eCollection 2025 Apr.
4
APOBEC Mutagenesis in Cancer Development and Susceptibility.
Cancers (Basel). 2024 Jan 15;16(2):374. doi: 10.3390/cancers16020374.
5
Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels.
Med Oncol. 2024 Jan 12;41(2):55. doi: 10.1007/s12032-023-02278-1.
7
Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination.
Nat Rev Genet. 2022 Aug;23(8):505-518. doi: 10.1038/s41576-022-00459-8. Epub 2022 Mar 7.
8
Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B.
ACS Pharmacol Transl Sci. 2021 Jul 19;4(4):1390-1407. doi: 10.1021/acsptsci.1c00091. eCollection 2021 Aug 13.
9
Small Molecule Inhibitors of Activation-Induced Deaminase Decrease Class Switch Recombination in B Cells.
ACS Pharmacol Transl Sci. 2021 May 7;4(3):1214-1226. doi: 10.1021/acsptsci.1c00064. eCollection 2021 Jun 11.

本文引用的文献

1
Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes.
Immunology. 2009 Mar;126(3):316-28. doi: 10.1111/j.1365-2567.2008.03050.x.
2
A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation.
PLoS Genet. 2009 Jan;5(1):e1000332. doi: 10.1371/journal.pgen.1000332. Epub 2009 Jan 9.
4
AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.
Cell. 2008 Dec 12;135(6):1028-38. doi: 10.1016/j.cell.2008.09.062.
5
6
MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation.
Immunity. 2008 May;28(5):630-8. doi: 10.1016/j.immuni.2008.04.002. Epub 2008 May 1.
7
MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase.
Immunity. 2008 May;28(5):621-9. doi: 10.1016/j.immuni.2008.03.015. Epub 2008 May 1.
8
Two levels of protection for the B cell genome during somatic hypermutation.
Nature. 2008 Feb 14;451(7180):841-5. doi: 10.1038/nature06547.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验